Ｐ０４２＿１０９　臨床医学系１／芦塚　柴田　木下　芦塚

Size: px

Start display at page:

Download "Ｐ０４２＿１０９　臨床医学系１／芦塚　柴田　木下　芦塚"

温音凤
5 years ago
Views:

1 C ALT Akehi Y, Tsutsumi Y, Tatsumoto A, Yoshida R, Ohkubo K, Takenoshita H, Kudo T, Ashida K, Anzai K, Yamashita T, Kawashima H, Ono J, Yanase T: Serum γ-glutamyltransferase, triglyceride and total cholesterol are possible prediabetic risk markers in young Japanese men. Endocrine Journal 57(11): , Ario K, Mizuta T, Eguchi Y, Kawaguchi Y, Oza N, Akiyama T, Iwane S, Takahashi H, Yasutake T, Ozaki I, Fujimoto K: Presence of esophageal varices is a risk factor for non-hemorrhagic death of hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatogastroenterology 57: , ADH TDS Ide T, Sata M, Sakisaka S, Nakamuta M, Fujiyama S, Mizuta T, Tahara K, Fujisaki K, Komorizono Y, Watanabe H, Morita Y, Tsubouchi H: Peginterferon-alpha-2b plus ribavirin therapy in patients with chronic hepatitis C as assessed by a multi-institutional questionnaire in Japan. Hepatol Res 40: , 2010.

2 Kitajima Y, Eguchi Y, Ishibashi E, Nakashita S, Aoki S, Toda S, Mizuta T, Ozaki I, Ono N, Eguchi T, Arai K, Iwakiri R, Fujimoto K: Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. J Gastroenterol 45: NASH Suppl S Mizuta T, Kawaguchi Y, Eguchi Y, Takahashi H, Ario K, Akiyama T, Oza N, Otsuka T, Kuwashiro T, Yoshimura T, Hisatomi A, Ozaki I: Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load. Dig Dis Sci 55: , Nagafuchi S, Katsuta H, Anzai K: Rituximab, B-Lymphocyte depletion, and beta-cell function. N Engl J Med 362: 761, Nagaishi R, Akehi Y, Ashida K, Higuchi-Tubouchi K, Yokoyama H, Nojiri T, Aoki M, Anzai K, Nabeshima K, Tanaka M, Ono J, Yanase T: Acute inflammatory syndrome and intrahepatic cholestasis caused by an interleukin-6-producing pheochromocytoma with pregnancy. Fukuoka Igaku Zasshi 101: 10-18, Nakashima M, Hamajima H, Xia J, Iwane S, Kawaguchi Y, Eguchi Y, Mizuta T, Fujimoto K, Ozaki I, Matsuhashi S: Regulation of tumor suppressor PDCD4 by novel protein kinase C isoforms. Biochimica et Biophysica Acta 1803: , Oeda S, Otsuka T, Akiyama T, Ario K, Masuda M, Taguchi S, Shono T, Kawazoe S: Recurrent acute pancreatitis caused by a gastric duplication cyst communicating with an aberrant pancreatic duct. Intern Med 49(14): , α a C β HCV Takahashi H, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Otuka T, Oeda S, Ario K, Iwane S, Akiyama T, Ozaki I, Fujimoto K: Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatol Res 40: , Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S, Kudo S, Miyoshi A, Miyazaki K, Fujimoto K: Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int 30: , 2010.

3 Acoustic Radiation Force Impulse Elastography Nursing Mook A E EB Matsuhashi S, Okawa T, Narisawa Y: Role of the tumor suppressor PDCD4 in the differentiation of the skin. In Dermatology Research Focus on Acne, Melanoma and Psoriasis, Ed. David E. Roth, pp , C G. I. Research Akiyama T, Mizuta T, Kawazoe S, Takahashi H, Nakashita S, Fujimoto M, Otsuka T: Whole-body insulin sensitivity index is a useful predictive marker for recurrence of hepatocellular carcinoma after curative treatment. 18th UEGW , 10, GUT 59 suppl. III, A130 (P0118). Eguchi Y, Kitajima Y, Mizuta T, Isoda H, Takahashi H, Anzai K, Ono N, Eguchi T, Koizumi S, Fujimoto K: The organ crosstalk between liver and skeletal muscle is a potentially influential factor in the diet and exercise therapy for nonalcoholic fatty liver disease. The 9th JSH Single Topic Conference. 2010, 11, Abstract 80 (poster 19). Eguchi Y, Mizuta T, Kawaguchi Y, Ozaki I, Ono N, Eguchi T, Fujimoto K: Visceral fat accumulation is the first and second hit pathogenesis for development of nonalcoholic fatty liver disease. The 2nd International Forum of the 96th Annual Meeting of the Japanese Society of Gastroenterology. 2010, 4, Hamajima H, Ozaki I, Iwane S, Takahashi H, Xia J, Kawaguchi Y, Eguchi Y, Matsuhashi S, Mizuta T, Fujimoto K: Regulation of tumor suppressor programmed cell death 4 (PDCD4) by protein kinase C isoforms in human hepatocellular carcinoma cells. 4th ILCA Annual Conference. 2010, 9, Final programme & Book of Abstracts, p35 (P-056). Ishibashi E, Eguchi Y, Mizuta T, Kitajima Y, Kawaguchi Y, Kuwashiro T, Matsunaga S, Oda Y, Ozaki I, Anzai K, Iwakiri R, Ono N, Eguchi T, Koizumi S, Fujimoto K: Excessive visceral fat accumulation plays both roles as the first and second hit in the pathogenesis and progression of nonalcoholic fatty liver disease. 45th Annual Meeting of the European Association for the Study of the Liver. 2010, 4, Journal of Hepatology 52 (Suppl.1): S144 (P-346). Kawaguchi T, Yatsuhashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M: Data mining revealed clinical feature profiling associated with staging of non

4 HBV- and non HCV-related hepatocellular carcinoma. AASLD 61th The Liver Meeting , 10, 29-11, 2. Final program, p296 (#1828). Kawaguchi Y, Mizuta T, Isoda H, Kuwashiro T, Oeda S, Iwane S, Takahashi H, Eguchi Y, Ozaki I: Wholebody insulin sensitivity is strongly associated with serum alpha-fetoprotein levels in patients with chronic hepatitis C. AASLD 61th The Liver Meeting , 10, 29-11, 2. Final program, p174 (#748). Kawazoe S, Nakashita S, Akiyama T, Otsuka T, Fujimoto M, Ozaki I, Mizuta T: Efficacy of transcatheter arterial chemoembolization therapy using CDDP in iodized oil for treatment of hepatocellular carcinoma: comparison with epirubicin regimens. 18th UEGW , 10, GUT 59 suppl. III, A209 (P0499). Kuwashiro T, Isoda H, Oeda S, Iwane S, Kawaguchi Y, Eguchi Y, Ozaki I, Mizuta T: Differences in survival prognosis in patients with hepatocellular carcinoma according to treatment era. 4th ILCA Annual Conference. 2010, 9, Final programme & Book of Abstracts, p 69 (P-179). Kuwashiro T, Mizuta T, Isoda H, Oeda S, Iwane S, Kawaguchi Y, Eguchi Y, Ozaki I, Fujimoto K: Insulin resistance is a main exacerbated factor of health-related quality of life (QOL) in chronic hepatitis C patients. 18th UEGW , 10, GUT 59 suppl. III, A323 (P1077). Mizuta T, Kawaguchi Y, Eguchi Y, Takahashi H, Iwane S, Kuwashiro T, Oeda S, Isoda H, Ozaki I: Visceral adiposity influences the antiviral effect of pegylated interferon plus ribavirin treatment for refractory chronic hepatitis C. AASLD 61th The Liver Meeting , 10, 29-11, 2. Final program, p196 (#926). Mizuta T, Kawaguchi Y, Eguchi Y, Takahashi H, Iwane S, Kuwashiro T, Oeda S, Isoda H, Ozaki I: An insulin resistance (IR)-oriented intervention program for chronic hepatitis C (CHC) patients can improve the virologic response to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy: a prospective study. AASLD 61th The Liver Meeting , 10, 29-11, 2. Final program, p199 (#949). Oeda S, Isoda H, Kuwashiro T, Iwane S, Kawaguchi Y, Eguchi Y, Ozaki I, Mizuta T: Good survival prognosis in overweight hepatocellular carcinoma patients. 4th ILCA Annual Conference. 2010, 9, Final programme & Book of Abstracts, p71 (P-185). Ono N, Okada T, Kuroki S, Eguchi T, Isoda H, Takahashi H, Eguchi Y, Mizuta T: Contrast-enhanced threedimensional ultrasonography to evaluate combination therapy with radiofrequency ablation and transcatheter arterial chemoembolization for hepatocellular carcinoma.12 th International symposium on Ultrasound contrast imaging. 2010, 12, Ozaki I, Hamajima H, Xia J, Takahashi H, Iwane S, Kawaguchi Y, Eguchi Y, Matsuhashi S, Mizuta T: Novel protein kinase C (PKC) isoforms PKC-δ and ε promote degradation of tumor suppressor programmed cell death 4 (PDCD4) in human hepatoma cells. AASLD 61th The Liver Meeting , 10, 29-11, 2. Final program, p155 (#569). g-ogtt suppls

5 p supplap SupplA P pica pica LINK p C PEG-IFNα-2a/Ribavirin SupplA P F BMI Suppl A P suppls C O TDS pi PEG-IFN /Ribavirin PEG-IFNα2a PEG-IFNα2b supplao ALT Suppl P β SupplA W

6 TRAb Metabolic disease C suppl C genotype 1b logiu/ml α2a Suppl A P suppla PD SupplA P P Suppl A P suppls Insulin resistance-oriented intervention program C PEG-IFN+ribavirin supplao C ALT metabolic factors Suppl P suppls

7 suppls Suppl A P Volume Navigation System suppl S PD I D US suppl S PD I suppl A Suppl O C suppla WS O PKC ε p P follow up suppls DPP

8 p SP HBs HBc B p WS NAFLD C p NASH C PD ACTH

9 EMCV Acoustic Radiation Force Impuls (ARFI) elastography HCV-RNA p D-US Volume Navigation System C Peg-IFN+Ribavirin IFNβ+Ribavirin p β β β β

10 β β

11 NAFLD B B PEG-IFNα-2a+Ribavirin IFNβ+Ribavirin C C PEG-IFN/Ribavirin PEG+R P EPOCH C PEG-IFN/RBV Hepatitis C Forum C C C NASH NASH JSG-NAFLD Sorafenib P P

12 P P C C metabolic factor P P P O B B d-roms C C PSY

plx-005/04

plx-005/04 (HCV) (HCC) 3 2 HCV HCV Flaviviridae) RNA 6 HCV ( 1a 2b 3c ) 1 HCV 70% HCV quasispecies HCV HCV ORF 10 NS NS3 / NS5B RNA RNA HCV HCV 100 5min 60 10h WHO HCV 3% 1.7 HCV 3.5 -HCV 3.2% -HCV 3.6% 2.9% 2.5%

Ｐ０４２＿１０９ 臨床医学系１／芦塚 柴田 木下 芦塚

Ｐ０４２＿１０９　臨床医学系１／芦塚　柴田　木下　芦塚